QRG Capital Management Inc. Acquires 5,168 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

QRG Capital Management Inc. lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 2.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,755 shares of the company's stock after purchasing an additional 5,168 shares during the period. QRG Capital Management Inc. owned 0.08% of Hims & Hers Health worth $5,548,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. SlateStone Wealth LLC boosted its position in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after buying an additional 628 shares during the period. Cim LLC raised its stake in Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after buying an additional 694 shares during the period. Finally, Harbour Investments Inc. raised its stake in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after buying an additional 833 shares during the period. Institutional investors own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 8,485 shares of the stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $506,978.75. Following the completion of the transaction, the insider now directly owns 712 shares of the company's stock, valued at approximately $42,542. This represents a 92.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $28.04, for a total value of $1,022,338.40. Following the transaction, the chief executive officer now directly owns 92,103 shares of the company's stock, valued at approximately $2,582,568.12. This trade represents a 28.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 751,034 shares of company stock valued at $36,486,522. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on HIMS shares. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Truist Financial dropped their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Stock Down 1.0%

Shares of Hims & Hers Health stock opened at $59.17 on Wednesday. The company has a market cap of $13.24 billion, a PE ratio of 85.75, a price-to-earnings-growth ratio of 2.25 and a beta of 2.09. The business has a 50 day moving average price of $46.36 and a 200-day moving average price of $38.60. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health's revenue was up 110.7% on a year-over-year basis. During the same period last year, the business posted $0.05 earnings per share. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.